NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06927180 2025-06-23
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting
NCT01340430 2024-05-09
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 2 Completed
NCT05659056 2024-04-16
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT02059876 2014-02-12
Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer
Guangdong Provincial People's Hospital
Phase 2 Unknown